|
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on BMS-247550 in Treating Patients With Advanced Pancreatic Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. BMS-247550 in Treating Patients With Advanced Pancreatic Cancer Clinical research trials and BMS-247550 in Treating Patients With Advanced Pancreatic Cancer health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including BMS-247550 in Treating Patients With Advanced Pancreatic Cancer. BMS-247550 in Treating Patients With Advanced Pancreatic Cancer Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a BMS-247550 in Treating Patients With Advanced Pancreatic Cancer clinical trial. Participants oftentimes recieve the most expert healthcare available for their BMS-247550 in Treating Patients With Advanced Pancreatic Cancer condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BMS-247550 in Treating Patients With Advanced Pancreatic Cancer  BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
For Condition: stage 3 pancreatic cancer,stage 4A pancreatic cancer,adenocarcinoma of the pancreas,stage 4B pancreatic cancer,recurrent pancreatic cancer,stage 2 pancreatic cancer
Status: No longer recruiting
Sponsor(s): Southwest Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.
Details: OBJECTIVES: - Determine the 6-month survival rate and time to treatment failure in patients with advanced pancreatic adenocarcinoma treated with BMS-247550. - Determine the frequency and severity of toxic effects of this drug in these patients. - Determine the complete and partial response in those patients with measurable disease treated with this drug. - Determine the pharmacokinetic profile of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive BMS-247550 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 6 months for 2 years and then annually until 3 years after registration. PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed advanced pancreatic adenocarcinoma - Distant metastases OR - Locoregional disease that has failed or is not amenable to locoregional therapy - No de novo locoregional disease - No known brain metastases PATIENT CHARACTERISTICS: Age: - Adult Performance status: - Zubrod 0-1 Life expectancy: - Not specified Hematopoietic: - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT or SGPT no greater than 2.5 times ULN - Alkaline phosphatase less than 2.5 times ULN Renal: - Creatinine no greater than 1.5 mg/dL Cardiovascular: - No recent myocardial infarction, unstable angina, or life-threatening arrhythmia Other: - Not pregnant or nursing - Fertile patients must use effective contraception - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in remission - No prior severe hypersensitivity reaction to drugs containing Cremophor EL - No active or uncontrolled infection - No severe psychiatric disorders PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior neoadjuvant, adjuvant, or primary immunotherapy for advanced pancreatic cancer - No concurrent anticancer immunotherapy Chemotherapy: - No prior neoadjuvant, adjuvant, or primary chemotherapy for advanced pancreatic cancer - No other concurrent anticancer chemotherapy Endocrine therapy: - No prior neoadjuvant, adjuvant, or primary hormonal therapy for advanced pancreatic cancer - No concurrent anticancer hormonal therapy Radiotherapy: - No prior neoadjuvant, adjuvant, or primary radiotherapy or chemoradiotherapy for advanced pancreatic cancer - Prior palliative radiotherapy allowed if at least 1 lesion remains outside of radiation field or at least 1 lesion has progressed since radiotherapy - No concurrent anticancer radiotherapy except palliative radiotherapy to non-target metastatic sites Surgery: - At least 2 weeks since prior surgery for pancreatic cancer and recovered Other: - No other concurrent anticancer therapy - No concurrent herbal or unconventional therapy (e.g., St. John's Wort)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertWhitehead, Study Chair, University of Texas
University of Rochester Medical Center
Rochester, New York, 14642
United States
University of Texas Medical Branch
Galveston, Texas, 77555-0565
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Veterans Affairs Medical Center - Charleston
Charleston, South Carolina, 29401-5799
United States
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
United States
Tripler Army Medical Center
Honolulu, Hawaii, 96859-5000
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813-2424
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7353
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
St. Louis University Health Sciences Center
St. Louis, Missouri, 63110
United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40502-2236
United States
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
United States
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
United States
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
United States
CCOP - Scott and White Hospital
Temple, Texas, 76508
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195-9001
United States
University of California Davis Cancer Center
Sacramento, California, 95817
United States
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
United States
CCOP - Columbia River Program
Portland, Oregon, 97225
United States
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
United States
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
United States
Loyola University Medical Center
Maywood, Illinois, 60153-5500
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0912
United States
Barrett Cancer Center
Cincinnati, Ohio, 45267-0501
United States
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4095
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
United States
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
United States
Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
Phoenix, Arizona, 85012
United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, 63141
United States
Oregon Cancer Institute
Portland, Oregon, 97239
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
Genesis Medical Center
Davenport, Iowa, 52804
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
Veterans Affairs Medical Center - Houston
Houston, Texas, 77030
United States
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
United States
Veterans Affairs Medical Center - Dallas
Dallas, Texas, 75216
United States
CCOP - Northwest
Tacoma, Washington, 98405-0986
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7845
United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
United States
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
United States
CCOP - Dayton
Dayton, Ohio, 45429
United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
United States
Additional Information:
Study ID Numbers: CDR0000068636; SWOG-S0107
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00016965
Other Adenocarcinoma Of The Pancreas Studies:
1. Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer
2. Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
3. Flavopiridol Plus Radiation Therapy Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
4. 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
5. Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
Related Studies:
Other adenocarcinoma of the pancreas Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
|
|
|
|
|
|
|
|
